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Vaccines were first introduced more than 200 years ago and have since played a key role in
the reduction of morbidity and mortality caused by infectious diseases. Many of the safest
and most effective vaccines in use today are based on attenuated live viruses, as they
mimic a live infection without causing disease. However, it is not always practical to take
this approach, such as when it may not be safe to do so (e.g., for viruses that cause chronic
infections such as HIV) or may not be feasible to manufacture (e.g., for viruses that do not
grow well in cell culture such as HCV). In addition, it may preferable in some cases to target
immune responses toward specific antigens from the pathogen, rather than the entirety
of the genome. In these cases, subunit vaccines consisting of antigens purified from the
pathogen or produced by recombinant DNA technology are being developed. However,
highly purified proteins are typically not inherently immunogenic, as they usually lack the
means to directly stimulate the innate immune system, and often require the addition of
adjuvants to enhance vaccine potency. Despite more than a century of human use, only a
few adjuvants are licensed today. However many adjuvants have been tested in humans
and are in advanced stages of development. Much of the early work on adjuvants discov-
ery and development was empirical producing safe and effective products, but without a
clear understanding of how they worked. Recent insight into the functioning of the innate
immune system has demonstrated its important role in triggering and shaping the adaptive
immune response to vaccines.
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INTRODUCTION
Adjuvants have been used in human vaccines for almost a cen-
tury, yet very few adjuvants are licensed for human use. This has
been due, in part, to a lack of understanding of their mechanism
of action. However, recent insights into the innate immune sys-
tem and its importance in initiating the adaptive immune response
have sparked the rational design and development the next genera-
tion of adjuvants. Several studies have validated one class of pattern
recognition receptors (PRRs) called Toll-like Receptors (TLRs) as
vaccine adjuvant targets. Various TLR agonists have been tested
in humans and the TLR4 agonist monophosphoryl-lipid A (MPL)
has been recently licensed in Europe and the USA for a vaccine
that prevents human papilloma virus (HPV) infection (Table 1).
This chapter will focus on both well established and exploratory
adjuvants to provide an overview of our current understanding of
vaccine adjuvant mechanism of action and how this information
may be used in the discovery of the next generation of products.
MODE OF ACTION OF ALUMINUM SALTS
Aluminum salts (aka alum) have been in wide use with human
vaccines for almost a century, with the first proof of concept stud-
ies in animal models published in 1926 (1). This class of adjuvants,
which includes aluminum phosphate, aluminum hydroxide, and
aluminum hydroxyphosphate, is a component of various viral and
bacterial vaccines such as diphtheria, tetanus, pertussis, hepatitis
A and B, rabies, anthrax, and others. Alum formulations are par-
ticulate in nature, to which the vaccine antigens are adsorbed,
albeit with distinct characteristics among the different forms of
alum salts (2). This adsorption can result in increased antigen
stability in vitro (3) and led to the initial assumption that alum
creates a depot in situ, thereby allowing slow release of antigen
over time and prolonged exposure to the immune system. How-
ever, four subsequent lines of evidence indicate that a depot effect
is likely not important for the adjuvant effect of alum. First, after
intramuscular injection,most of the antigen diffuses away from the
injection site within hours of administration (4). Second, adminis-
tration of antigen adsorbed to alum does not increase the half-life
of antigen in situ (2). Third, excision of the injection site within a
few hours after vaccine administration did not reduce the magni-
tude of the ensuing antigen-specific immune responses (5). Finally,
Munks et al. demonstrated that alum induces fibrin-dependent
nodules at the injection site, but that these nodules do not play a
part in the adjuvant effect (6). Taken together, these data strongly
rule out any role of antigen depot in alum’s mode of action.
It has long been known that physical interaction of the vaccine
antigen with alum is necessary for the full adjuvant effect (1), sug-
gesting that alum functions, at least in part, as a delivery system.
This could be accomplished by facilitating co-delivery of the anti-
gen and adjuvant to the appropriate physical location, thereby
ensuring that the inflammatory response to alum is directed
toward the co-administered antigen. Indeed, alum induces local
inflammation at the injection site, irrespective of whether antigen
has been adsorbed (7) and the enhancement of antigen-specific
immunity is often lost if the antigen and alum are administered at
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Table 1 | Adjuvants evaluated in humans.
Adjuvants Class Vaccine
TLR-DEPENDENTADJUVANTS
AS04 Alum-adsorbed TLR4
agonist (31)
HBV, HPV
RC-529 HBV
CpG 7909 TLR9 agonist (39) HBV, Influenza, etc.
CpG1018 HBV, Cancer
IC31 TB
Imiquimod TLR7 agonist (43) Cancer
Flagellin TLR5 agonist (42) Influenza
AS01 Combo TLR4 Malaria
AS02 Combo TLR4 Malaria, TB, Cancer
AS15 TLR4+TLR9 Cancer
TLR-INDEPENDENTADJUVANTS
Alum Mineral salts (1), (2) Diphtheria, tetanus,
pneumococcus, etc.
MF59 Oil-in-water emulsion
(22), (29)
Influenza
AS03 Influenza
AF03 influenza
Virosomes Liposomes HAV
Iscomatrix Combination HCV, influenza, HPV, cancer
Montanide ISA51 Oil-in-water emulsion Malaria, HIV, cancer
Montanide ISA720 Malaria, HIV, cancer
LT Bacterial toxins Influenza, ETEC
LTK63 Influenza, TB, HIV
TLR-dependent and TLR-independent adjuvants have been tested in human clin-
ical trials. Those shown in green are components of licensed human vaccines,
while those in orange have been tested in clinical trials, but are not yet approved.
References cited are provided for those adjuvants discussed in detail in the text.
ETEC, enterotoxigenic E. coli; HAV, hepatitis A virus; HBV, hepatitis B virus, HCV,
hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papilloma
virus; LT, labile toxin; TB, tuberculosis.
separate locations (8). Particulate vaccine formulations generally
are more readily internalized by antigen-presenting cells (APCs)
than are soluble antigens and the same is true for alum-adsorbed
antigens. The mechanism by which antigen uptake is facilitated is
not yet clear, but a recent study suggested that this may occur in the
absence of uptake of alum by APCs. Crystalline alum was shown
to bind lipids on the surface of APCs and trigger a cellular acti-
vation cascade leading to initiation of an immune response, but
without itself being internalized by the cells (9), suggesting an indi-
rect role in delivering antigen into the antigen processing pathway.
These results are in contrast with a previous study using confocal
microscopy showing that alum was internalized by APCs (10). In
addition, alum crystals can be found in the endosomes of blood
cells using electron microscopy (Latz, personal communication).
The innate immune system is a complex network of sensing
pathways that function to rapidly alert the host to infections,
cancers, and cellular dysfunction. In the context of vaccines, it
has become clear that signaling the innate immune system is an
important early aspect in the development of an effective antigen-
specific immune response and is one of the key roles for a vaccine
adjuvant. In vitro studies have shown that alum can facilitate
activation of DCs, as measured by increased surface expression
of co-stimulatory molecules CD80 and CD86, and secretion of
cytokines (11). It is not known whether this is the result of direct
cellular signaling and a molecular target, if one exists, has not
yet been identified. Injection of vaccines containing alum elicits
profound broad local effects on the immune system. Within a few
hours after injection, pro-inflammatory cytokines are released and
there is an influx of inflammatory monocytes followed by dendritic
cells (DCs), natural killer (NK) cells, neutrophils, and eosinophils
by 24 h (12, 13). During this time, a constellation of genes are up-
regulated, including those encoding cytokines and chemokines (7)
which may function to facilitate the recruitment and activation of
APCs at the site of injection. These APCs may then internalize vac-
cine antigens and migrate to the draining lymph node to prime
lymphocytes (14).
The molecular mechanisms involved in the response to alum
are being elucidated, but more than one pathway may be involved
and there are some conflicting results. Unlike the immune stim-
ulatory properties of TLR agonists, which require the adaptor
molecules MyD88 and TRIF, the adjuvant effects of alum are not
impaired in the absence of these proteins (15), suggesting that
alum does not signal in a TLR-dependent fashion. Several studies
performed in vitro on mouse and human cells have demonstrated
that alum can activate the Nlrp3 inflammasome complex, which
is required for the processing of several key pro-inflammatory
cytokines including IL1. The molecular mechanism of activation
of Nlrp3 is not clear, however one report has shown that alum after
internalization destabilizes the endosome releasing proteases that
are required for Nlrp3 inflammasome activation and IL1 release
(10). Consistent with these in vitro studies, others have shown
Nlrp3 to be required for alum adjuvanticity in mice (16, 17).
However, studies performed in other laboratories using different
antigens and immunization protocols demonstrated that in some
cases Nlrp3 may not be implicated [(18–20)]. Indirect effects of
alum can be induced via the release of certain molecules by cells,
which then can elicit subsequent adjuvant activity. For example,
alum stimulates the induction of uric acid (12), which is produced
normally as a damage-associated molecular pattern (DAMP) by
injured cells. Released uric acid is then internalized by and activates
APCs via the inflammasome, thereby providing a downstream,
secondary immunostimulatory signal in response to immuniza-
tion with alum-containing vaccines. In a similar manner, alum
stimulates the release of dsDNA from dying cells and this DAMP
seems to play a role in adjuvant activity by promoting antigen
presentation to helper T cells (20, 21). In summary, the immunos-
timulatory effects of alum are broad, rapid, and seem to involve
multiple pathways, both direct and indirect. More investigation
will be required to fully elucidate these pathways.
MODE OF ACTON OF OIL-IN-WATER EMULSIONS
Oil-in-water emulsions are licensed for use in human influenza
vaccines. These include MF59, which was originally licensed in
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1997 for influenza vaccines for the elderly, and AS03, which like
MF59 was recently approved for pandemic influenza vaccines.
MF59 consists of uniform particles ∼160 nm in size generated
by microfluidics technology and its main constituents are the nat-
urally occurring oil squalene and the non-ionic surfactants Tween
80 and Span 85. There is a large human clinical experience with
MF59, with almost 100 million doses administered over the past
15 years, demonstrating that the adjuvant is safe, well tolerated,
effective at increasing vaccine potency, able to reduce the dose of
antigen required, and elicits broad-based immunity (22).
Like alum,MF59 was initially thought to exert its adjuvant effect
by the formation of an antigen depot. However, studies conducted
with labeled MF59 have shown that the adjuvant is quickly drained
from the injection site, that only ∼10% of the adjuvant remains
at the injection site 6 h after intramuscular administration (23),
and that the presence of MF59 does not influence the distribution
or the half-life of the co-administered antigen (24). In addition,
unlike alum, the adjuvant effects of MF59 can be maintained even
when the antigen alone is administered up to 24 h after injection
of MF59 at the same site (23). Taken together, these data are not
consistent with the hypothesis that MF59 acts as an antigen depot,
rather MF59 appears to create an “immunocompetent environ-
ment” within the muscle that could facilitate the development of
antigen-specific immune responses.
Subsequent work has suggested that MF59 can function as
an antigen delivery system, albeit in an indirect fashion. Stud-
ies conducted on cells in vitro demonstrated that MF59 increased
phagocytosis and pinocytosis, and promoted antigen uptake by
APCs (25). In that study, neither monocyte-derived DCs (Mo-
DCs) nor myeloid DCs (mDCs) isolated from human blood were
directly activated by MF59. Rather, MF59 stimulated monocytes,
macrophages, and granulocytes to produce the chemokines CCL2,
CXCL8, CCL3, and CCL4. In addition, stimulated monocytes
underwent phenotypic changes in accordance with their differ-
entiation toward DCs. These data suggested that MF59 does not
directly target DCs to internalize antigen, but may act upstream
by inducing recruitment of DC precursors and their subsequent
differentiation (25).
In vivo studies have shown that fluorescently labeled MF59
was found to be co-localized together with the co-administered
antigen in immature DCs (DEC205+ MHCII+) infiltrating the
mouse muscle at 48 h after injection There was a strong influx of
mononuclear cells to the injection site, with a significant pro-
portion of the cells identified as macrophages (F4/80-positive
cells) and a minor population of DCs (CD11c-positive cells).
This cellular influx induced by MF59 was significantly impaired
in CCR2-/- knockout mice, suggesting that MF59 triggers cell
recruitment events, at least partially mediated by CCR2, that are
required for adjuvanticity(25). In agreement with this hypoth-
esis, microarray analysis demonstrated that MF59 activates the
expression of genes encoding cytokines (IL-1b, IL-2), chemokines
(Ccl2, Ccl4, Ccl5, Ccl12, Ccl10), and adhesion molecules in the
mouse muscle. MF59 also induced the up-regulation of genes
coding for Ccr2 and its ligands (7). Furthermore, MF59 pro-
moted a more rapid influx of CD11b+ cells in the muscle
compared to other adjuvants (such as alum and CpG oligonu-
cleotides). Some of the genes up-regulated rapidly after MF59
administration were used as biomarkers to identify MF59 tar-
get cells. Confocal microscope analysis showed that two of these
biomarkers, JunB and Pentraxin 3, were up-regulated in muscle
fibers following MF59 treatment, demonstrating that muscle cells
are a target of MF59 in vivo (7). A subsequent study in mice
by Calabro et al. characterized in detail the kinetics and phe-
notype of the immune cells recruited by MF59 to the injection
site (26). Infiltration of granulocytes, such as neutrophils and
eosinophils, and potential APCs, such as monocytes, macrophages,
and DCs were observed. MF59 was found to be a much stronger
activator of cell recruitment than alum and promoted a more
efficient uptake of vaccine antigen at injection site. In addi-
tion, MF59 significantly increased the number of antigen-loaded
APCs in draining LNs compared to alum or non-adjuvanted
vaccine (26).
In a recent study, the effects of TLR-independent (alum and
MF59) and TLR-dependent (R848, CpG, and Pam3CSK4) adju-
vants were characterized using DNA microarray in vitro and
in vivo (27). The transcription profiles from adjuvant-treated cells
in vitro and injected mouse muscles and their draining lymph
nodes (LN) in vivo were quite different for the two different adju-
vant classes. In contrast to TLR agonists, MF59 and alum did
not modulate transcription of cytokine mRNAs by splenocytes
in vitro. After intramuscular injection, MF59-induced a localized
immunostimulatory environment in the muscle but did not mod-
ulate the transcriptome in the draining LN and did not induce
any antigen-independent activation of B and T cells. In contrast,
some of the TLR agonists (such as R848) elicited effects distant
from the injection site and modulated gene transcription in LNs
in an antigen-independent matter leading to polyclonal T and B
cell activation. Finally, immune responses enhanced by MF59 to
tetanus and influenza antigens were found to be independent of
the presence of interferon type I, unlike R848 which displayed
dependency on this cytokine (27).
It has been proposed that adjuvanticity of some particulate
adjuvants (including alum) depends on the activation of a protein
complex called the Nlrp3 inflammasome that processes certain
pro-inflammatory cytokines like pro-IL1β through Caspase 1 (12,
16). Two independent studies have demonstrated that MF59-
induced adjuvant effects are independent of Nlrp3 and Caspase
1 (19, 28). However, it was shown that the effects of MF59
depend on the apoptosis-associated speck-like protein contain-
ing CARD (ASC), which is a common adaptor of inflammasome
complexes (28). Hence, it is possible that ASC might also have
an inflammasome-independent function or that inflammasomes
different from Nlrp3 might play a role. Experiments conducted
using mice deficient in innate immune pathways have shown that
enhancement of immune responses to a recombinant meningo-
coccus B vaccine by MF59 required the adaptor molecule MyD88
(19). Yet, MF59 has not been shown to be an agonist of any of the
TLR that depend on MyD88 for signaling. Possible explanations
include that MF59 induces the release of endogenous TLR agonists
at the injection site or that MF59 targets other MyD88-dependent
pathways involving the receptors for IL1 family cytokines (IL1R,
IL18R, IL33R) or the TACI receptor. As is the case for alum, fur-
ther studies are required to better understand the mode of action
of MF59.
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AS03 is another squalene-based emulsion, but differs from
MF59 in the absence of the Span85 surfactant and, more impor-
tantly, in the presence of α-tocopherol. These differences in the for-
mulation markedly affect the biological activity of the emulsions,
mainly due to the immunostimulatory activity of α-tocopherol.
Unlike MF59, which activates innate immunity only locally at
the injection site, AS03 triggers innate immune responses in the
injected muscle and in the draining LN of immunized mice. This
activation of the lymph node is independent of the antigen but
depends on the presence of α-tocopherol (29).
MODE OF ACTION OF TOLL-LIKE RECEPTOR AGONISTS
In addition to alum and oil-in-water emulsions, which have been
used extensively in human vaccines, various other adjuvants have
been evaluated in human clinical trials (see Table 1). Many of
these experimental adjuvants are known to target elements of
innate immune signaling pathways, in particular the TLRs but
also Nod-like receptors, RIG-I-like receptors, and C-type lectin
receptors. These PRRs function to provide a first line of immune
defense against incoming pathogens by interacting with molec-
ular signatures commonly found in microbes but not in host
cells (so called pathogen associated molecular patterns or PAMPs).
Examples include, but are not limited to, dsRNA and ssRNA from
viruses, CpG motifs from bacterial DNA, certain lipids, lipopep-
tides and glycans from bacterial cell wall components, flagellin
from bacteria, zymosan from yeast, and profilin from protozoa.
The importance of the innate immune system in potentiating the
adaptive immune response is well established and the critical role
this signaling plays in adjuvant function is becoming appreciated.
It is likely that the potency of vaccines based on whole organisms
is due, at least in part, to stimulation of TLRs. For example, the
Yellow fever vaccine, which is based on an attenuated live virus,
has been shown to interact with at least four TLRs (30). For this
reason, agonists of TLRs and other PRRs are attractive targets as
vaccine adjuvants. Following is a brief summary of the key aspects
of the TLR agonists that have been achieved proof of concept in
humans.
TLR4 is a cell surface PRR that recognizes several PAMPs,
including lipopolysaccharides (LPS) from bacteria, and is the tar-
get for the well-established adjuvant MPL. Normally, LPS is toxic
and not appropriate for use in human vaccines. However, MPL
is based on the TLR4-active element of LPS from Salmonella and
its toxicity is ∼1000-fold lower than LPS. MPL is an active and
safe component of licensed vaccines against hepatitis B and HPV
(see Table 1), and more than 100,000 human doses have been
administered (31). This TLR4 agonist is typically used in combi-
nation with alum and as a consequence enhances both protective
antibody responses, as well as promoting a Th1-type of helper T
cell response (32). Preclinical and clinical evaluation of MPL and
MPL-like synthetic analogs has demonstrated its broad utility as
a vaccine adjuvant in animal models of infectious (33, 34) and
non-infectious diseases, including allergy (35) and cancer (36).
TLR9 is an endosomal PRR that recognizes DNA with certain
motifs containing unmethylated CpG residues more often found
in microbial than eukaryotic DNA. Adjuvants directed toward this
TLR are perhaps the best studied and most complex of the TLR
agonists. For example, there are various types of these CpG motifs,
all of which are dependent upon TLR9 but have different quali-
tative and quantitative effects on the immune response (37) In
addition, CpG motifs exhibit species-specific differences (38) that
have complicated development of this class of adjuvants. Nev-
ertheless, TLR9 agonists are being evaluated in the later stages of
clinical development for infectious disease and allergy indications.
For example, a commercial hepatitis B virus (HBV) vaccine formu-
lated with CpG enhanced vaccine potency in humans, as measured
by higher levels of protective antibodies with more rapid kinet-
ics and with fewer immunizations than the vaccine alone (39).
Although the currently licensed HBV vaccines are very effective, a
major limitation is that certain individuals (∼5–10% of the general
population depending on geography) do not respond to vaccina-
tion even after multiple administrations. The addition of CpG
to the vaccine reduces the proportion of these non-responders
(40), demonstrating that adjuvants may provide a solution to this
limitation. CpG can be effective as a vaccine adjuvant by simple
mixing with antigen, but increased potency and lower require-
ments for antigen dose can be achieved by conjugation of CpG
directly to antigen. This approach has been particularly useful for
modulation of immune responses to allergens and human trials
are underway as a potential therapeutic intervention for treatment
of allergic responses (41).
TLR5 is a cell surface PRR that recognizes a particular bacterial
protein called flagellin. Because this TLR agonist is proteinaceous
in nature, it offers the possibility of creating recombinant fusion
proteins containing both an antigen and adjuvant. This approach
has been shown to be effective in animal models for influenza
using a fusion between flagellin and the hemagglutinin protein.
Early human clinical trials have demonstrated proof of concept for
the safety and utility of this strategy (42), and opens the possibility
of exploring the use of other protein-based TLR agonists such as
zymosan and profilin. One potential pitfall of this methodology
is the uncertain effects on structural integrity and preservation of
important B cell epitopes in the antigen.
TLR7 and 8 are related PRRs found in the endosomes of
various immune cells and function to recognize certain ssRNA
molecules rich in uridine residues, as is found in viral RNA.
Interaction with these TLRs can be mimicked using synthetic
compounds, such as imidazoquinolines and the guanosine ana-
log Loxoribine (43). TLR7 activation by the imidazoquinoline
imiquimod is an effective topical treatment approved for human
use against HPV-induced genital warts and basal cell carcinoma.
Imiquimod and a potent related molecule resiquimod have been
shown to function as vaccine adjuvants enhancing both antibody
and T cell responses in various models including non-human
primates (44). Some human vaccine clinical trials have been con-
ducted using topical application of TLR7 agonists at the vaccine
injection site, but so far there has been no observed adjuvant
effect (45).
TLR3 is an endosomal PRR that recognizes dsRNA, such as is
produced during cytoplasmic viral replication. Poly(I:C), which
is composed of a mixture of dsRNA species varying considerably
in size, has been demonstrated to be an effective vaccine adjuvant
in various animal models and for cancer immunotherapy (46). A
synthetic dsRNA of defined size and sequence is under develop-
ment for use as an adjuvant for an mRNA-based vaccine. This two
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component RNA vaccine (mRNA to mediate antigen expression
in situ and non-coding dsRNA to stimulate the innate immune
system via TLR3) is efficacious in animal models of influenza and
cancer (47), and has been shown to be safe and immunogenic as a
cancer vaccine strategy in humans (48).
SUMMARY
The beneficial effects of vaccine adjuvants can be manifest in vari-
ous ways, including (1) increasing vaccine potency to attain higher
levels of immunogenicity and protective efficacy (e.g., alum for
various viral and bacterial vaccines), (2) reducing the dose of anti-
gen required for effectiveness (e.g., MF59 for influenza vaccines),
(3) increasing the speed and reducing the number of immuniza-
tions required to achieve effectiveness (e.g., AS04 for hepatitis B
vaccine), (4) broadening the repertoire of antibody responses (e.g.,
MF59 for influenza vaccines), and (5) modulating the phenotype
of T cell responses. Adjuvants have been in use for these purposes
for most of the past century, but until relatively recently adjuvant
development has been predominated by empiricism. However, our
growing insight into innate immune signaling pathways and the
key roles PRRs play in the recognition of microbial signatures
provides an opportunity to take rational approaches in the design
and optimization of new vaccine adjuvants (as demonstrated in
the preceding section). Knowledge of the molecular target (e.g.,
a specific TLR) enables vaccine developers to harness the power
of drug discovery tools, such as (1) high throughput screening to
mine large libraries of small molecular compounds for a partic-
ular property or activity, (2) medicinal chemistry to design and
synthesize families of related compounds, and (3) computational
approaches to elucidate structure activity relationships and aid
in the optimization of adjuvant candidates (49). However, this
process of optimization will create strong pro-inflammatory mol-
ecules, hence it will be important to strike the correct balance
between potency and safety. To this end, these small molecule
immune potentiators can be designed not only to maximize ben-
eficial immunologic effects, but also to minimize undesirable side
effects by (1) manipulating pharmacokinetic properties that affect
biodistribution of the compounds (e.g., limit systemic exposure)
and (2) facilitating interaction with formulations designed to
ensure localized co-delivery of the antigen and immunostimu-
latory compound. This balance will be further influenced by the
relative risks versus benefits of including an adjuvant in a vac-
cine. For example, the tolerance for added risk of side effects by
inclusion of an adjuvant in a vaccine will be very different for pre-
vention of a low likelihood event in healthy people (e.g., anthrax
exposure) compared to treatment of an ongoing life-threatening
condition (e.g., cancer). The breadth of molecular targets for small
molecule compounds coupled with the diversity of disease targets
and patient populations for vaccines has created a fertile area for
novel adjuvant discovery and development.
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